WO1998006425A1 - Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine - Google Patents
Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine Download PDFInfo
- Publication number
- WO1998006425A1 WO1998006425A1 PCT/SE1997/001344 SE9701344W WO9806425A1 WO 1998006425 A1 WO1998006425 A1 WO 1998006425A1 SE 9701344 W SE9701344 W SE 9701344W WO 9806425 A1 WO9806425 A1 WO 9806425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactoferrin
- lactoferricin
- treatment
- pharmaceutical composition
- prevention
- Prior art date
Links
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 85
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 85
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 83
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 82
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 82
- 101800004361 Lactoferricin-B Proteins 0.000 title claims abstract description 40
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 title claims abstract description 39
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 24
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 23
- 230000002265 prevention Effects 0.000 title claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 208000019206 urinary tract infection Diseases 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- 206010009887 colitis Diseases 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 235000013350 formula milk Nutrition 0.000 claims abstract description 5
- 241000283690 Bos taurus Species 0.000 claims description 7
- 239000000413 hydrolysate Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 16
- 102000050459 human LTF Human genes 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 229940100601 interleukin-6 Drugs 0.000 description 13
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 11
- 229940072440 bovine lactoferrin Drugs 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000000110 microvilli Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 108010071397 lactoferrin receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 3
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the iron-binding lactoferrin is also present in specific granules of polymorphonuclear leucocytes and in other exocrine secretions than milk such as saliva, tears and bronchial mucus, as well as cervical secretion, amni- otic fluid, decidua, and trophoblasts (see e.g. Montreuil J., et al., Isolement d'une lactosiderophiline du lait de appropriate, CR Acad. Sci. Paris 250 D: 1736-37, 1960; Montreuil J., et al., Preparation et proprietes de la lactosiderophiline (lactotransferrine) du fait de an, Biochim. Biophys.
- IL-6 response when added to fresh monocytes or cultured monocytic cells.
- Prevention refers to minimizing, reducing or sup- pressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.
- a “patient” is a subject at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition.
- An “effective amount” is an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious condition.
- the pharmaceutical composi- tion according to the present invention is formulated for oral administration.
- lactoferrin and lactoferricin used according to the present invention can e.g. be obtained through isola- tion and purification from natural sources, such as human milk, through use of genetic engineering techniques, such as recombinant expression or direct production in genetically altered animals, or through chemical synthesis.
- the lactoferricin can also be obtained by enzymatic degrada- tion of lactoferrin (hydrolysate) .
- the lactoferrin used according to the present invention is preferably human lactoferrin or bovine lactoferrin, and it is preferably administered as a hydrolysate.
- the lactoferricin used according to the present in- vention is preferably human lactoferricin or bovine lactoferricin.
- the pharmaceutical composition comprising lactoferrin and/or lactoferricin according to the present invention is particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by the fungus Candida albicans.
- the pharmaceutical composition according to the present invention is also well suited for preventive medical care by reducing the risk of developing urinary tract in- fection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications .
- lactoferrin and/or lactoferricin in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants.
- Fig. 1 a - d illustrate bacterial recovery from the kidney (a and b) and bladder (c and d) , respectively, of C3H/Tif and C3H/HeN mice infected with E. coli in the urinary tract and perorally given human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
- LF hum human lactoferrin
- LF bov bovine lactoferrin
- Fig. 5 illustrates the cytokine concentration in serum from mice with experimentally induced colitis after treatment with bovine lactoferrin (LF bov) compared to a control group not receiving lac- toferrin.
- LF bov bovine lactoferrin
- lactoferrin The antibacterial and anti-inflammatory properties of lactoferrin were explored by studying the effects of lactoferrin given to mice (C3H/Tif and C3H/HeN) with experimentally induced urinary tract infection (UTI) .
- Urine samples from the mice were collected 0, 2, 5, and 24 hours after infection. 50 ⁇ l of each of the undiluted urine samples were cultured. The number of leucocytes in uncentrifuged urine was analyzed for each sample. The remaining urine from each animal at each sampling time was centrifuged and saved for IL-6 analysis. After 24 h the mice were bled and killed. The bladder and kidneys were taken out aseptically. The organs were homogenized, and serial dilutions thereof (bladder 1/1, 1/10, kidneys 1/1, 1/10, 1/100, 1/1000) were cultured on Drigalsky plates.
- a significant p value should be adjusted to p ⁇ 0.025 t illustrates a significant increase in the treatment group compared to the infected but untreated control group.
- I illustrates a significant decrease in the treatment group compared to the infected but untreated control group.
- lactoferrin both human and bovine significantly decreased the number of bacteria in the urinary tract of the infected mice, compared to the control group.
- Acute colitis was induced in C57BI/6J mice by giving 5% dextransulphate in the drinking water for 6 days.
- Human lactoferrin was orally given to ten mice twice a day in a dose of 1 mg/mouse, starting from day 3 of the experiment.
- Two control groups (in total 17 mice) were given the same volume of drinking water or bovine serum albumin (BSA) (2 mg per mouse and day) .
- BSA bovine serum albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant de la lactoferrine et/ou de la lactoferricine et destinée au traitement et/ou à la prévention d'infections, d'inflammations et/ou de tumeurs. L'invention se rapporte également à l'utilisation de lactoferrine et de lactoferricine dans la production d'une composition pharmaceutique destinée au traitement et/ou à la prévention d'infections, d'inflammations et de tumeurs, ainsi qu'à un procédé de traitement et/ou de prévention d'infections, d'inflammations et/ou de tumeurs, ce procédé consistant à administrer de la lactoferrine et/ou de la lactoferricine. L'invention est notamment conçue pour le traitement et/ou la prévention d'infections de l'appareil urinaire et les colites. De préférence, on administre oralement la lactoferrine et/ou lactoferricine de l'invention. En outre, on peut inclure dans un aliment pour nourrissons la composition comprenant la lactoferrine et/ou lactoferricine.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97935939A EP0920331A1 (fr) | 1996-08-12 | 1997-08-12 | Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine |
| JP50964098A JP2001504447A (ja) | 1996-08-12 | 1997-08-12 | ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防 |
| CA002263416A CA2263416A1 (fr) | 1996-08-12 | 1997-08-12 | Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine |
| AU38727/97A AU3872797A (en) | 1996-08-12 | 1997-08-12 | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2376196P | 1996-08-12 | 1996-08-12 | |
| US60/023,761 | 1996-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998006425A1 true WO1998006425A1 (fr) | 1998-02-19 |
Family
ID=21817049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1997/001344 WO1998006425A1 (fr) | 1996-08-12 | 1997-08-12 | Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0920331A1 (fr) |
| JP (1) | JP2001504447A (fr) |
| AU (1) | AU3872797A (fr) |
| CA (1) | CA2263416A1 (fr) |
| WO (1) | WO1998006425A1 (fr) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001730A1 (fr) * | 1998-07-06 | 2000-01-13 | A+ Science Invest Ab | Peptides reposant sur la sequence de la lactoferrine humaine et leur utilisation |
| WO2000012541A3 (fr) * | 1998-08-28 | 2000-06-08 | Alpharma As | Peptides bioactifs |
| JP2002241301A (ja) * | 2001-02-15 | 2002-08-28 | Meiji Milk Prod Co Ltd | 炎症に伴う症状の軽減剤 |
| WO2001019852A3 (fr) * | 1999-08-31 | 2002-09-12 | Alpharma As | Preparation de peptides |
| EP0980261A4 (fr) * | 1997-05-03 | 2003-04-23 | Univ Texas | Methodes de prevention et de traitement du desequilibre metabolique induit par insulte chez les humains et des animaux |
| WO2003082921A1 (fr) * | 2002-04-03 | 2003-10-09 | Fonterra Research Centre Limited | Lactoferrine |
| WO2003088914A3 (fr) * | 2002-04-18 | 2004-02-26 | Univ Iowa Res Found | Procede pour inhiber et traiter de films biologiques au moyen de chelateurs metalliques |
| GB2396810A (en) * | 2002-12-20 | 2004-07-07 | Richard John Cleeve | Bird Feed |
| WO2006001766A1 (fr) * | 2004-06-23 | 2006-01-05 | Nestor Medical Ab | Composition comprenant de l'acide lactique et de la lactoferrine |
| US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| WO2009050279A1 (fr) | 2007-10-19 | 2009-04-23 | Pharmasurgics In Sweden Ab | Nouveaux peptides synthétiques et leur utilisation |
| US7901879B2 (en) | 2002-05-10 | 2011-03-08 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| US8105615B2 (en) | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2012094098A1 (fr) * | 2011-01-05 | 2012-07-12 | Mead Johnson Nutrition Company | Composition contenant des protéines de lait thermolabiles et procédé de préparation associé |
| EP2481751A1 (fr) | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Homme peptides dérivés de lactoferrine |
| US8283315B2 (en) | 1998-08-28 | 2012-10-09 | Lytix Biopharma As | Inhibition of tumour growth |
| WO2014097123A1 (fr) | 2012-12-17 | 2014-06-26 | Progine Farmaceutici S.R.L. | Composition pour application topique comprenant de la lactoferrine |
| US8815812B2 (en) | 2007-11-14 | 2014-08-26 | Inger Mattsby-Baltzer | Synthetic arginine substituted peptides and their use |
| EP2992894A1 (fr) | 2014-09-05 | 2016-03-09 | Progine Farmaceutici Srl | Formulations vaginales pour prévenir et traiter des infections vaginale et cervico-vaginale |
| WO2021222584A3 (fr) * | 2020-04-29 | 2021-12-02 | The Regents Of The University Of Michigan | Inhibition d'entrée virale du sras-cov-2 par administration de lactoferrine et ses utilisations |
| CN116036054A (zh) * | 2023-03-07 | 2023-05-02 | 广州见华医学科技有限公司 | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 |
| CN116327740A (zh) * | 2023-03-07 | 2023-06-27 | 广州见华医学科技有限公司 | 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途 |
| EP4523699A1 (fr) * | 2023-09-15 | 2025-03-19 | FB Dermo srl | Composition dermatologique anti-inflammatoire comprenant du glycerophosphoinositol, un hydrolysat de lactoferrine et un cannabinoïde, notamment pour le traitement de la dermatite séborrhéique |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5872131B2 (ja) * | 2006-11-29 | 2016-03-01 | ロート製薬株式会社 | 抗真菌医薬組成物 |
| JP2011051914A (ja) * | 2009-08-31 | 2011-03-17 | Obihiro Univ Of Agriculture & Veterinary Medicine | 低温殺菌処理ホエータンパク濃縮物を含む腸管炎症抑制剤 |
| JP5177901B2 (ja) * | 2009-12-02 | 2013-04-10 | 株式会社明治 | 栄養組成物 |
| JP5763024B2 (ja) * | 2012-09-07 | 2015-08-12 | 株式会社明治 | 栄養組成物 |
| JPWO2016056665A1 (ja) * | 2014-10-08 | 2017-08-10 | 学校法人慶應義塾 | 白血球の細胞外トラップ形成の阻害剤 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0506651A2 (fr) * | 1991-03-25 | 1992-09-30 | IMMUNO Aktiengesellschaft | Préparations pharmaceutiques sur la base de protéines plasmatiques |
| EP0568200A2 (fr) * | 1992-04-02 | 1993-11-03 | Immuno Japan Inc. | Compositions pharmaceutiques et alimentaires contenant des transferrines et des agents antibactériens pour améliorer l'activité des dépenses immunitaires et pour le traitement d'infections |
| EP0629347A1 (fr) * | 1992-01-23 | 1994-12-21 | Morinaga Milk Industry Co., Ltd. | Agent antibacterien et traitement d'articles au moyen de cet agent |
| EP0730868A1 (fr) * | 1995-02-17 | 1996-09-11 | Tamotsu Satoh | Médicaments formulés pour le traitement d'inflammations orales et produits alimentaires préparés pour le traitment et la prévention de la stomatite |
| EP0753308A2 (fr) * | 1995-07-12 | 1997-01-15 | Gambit International Limited | Utilisation de lactoferrine pour la thérapie de maladies infectieuses aigues ou récurrentes causées par Streptococcus pyogenes ou d'autres bactéries pathogènes gram-positives intracellulaires |
| WO1997005884A1 (fr) * | 1995-08-07 | 1997-02-20 | New England Medical Center Hospitals, Inc. | Aliment lacte pour nourrissons et additifs correspondants |
-
1997
- 1997-08-12 WO PCT/SE1997/001344 patent/WO1998006425A1/fr not_active Application Discontinuation
- 1997-08-12 EP EP97935939A patent/EP0920331A1/fr not_active Withdrawn
- 1997-08-12 CA CA002263416A patent/CA2263416A1/fr not_active Abandoned
- 1997-08-12 AU AU38727/97A patent/AU3872797A/en not_active Abandoned
- 1997-08-12 JP JP50964098A patent/JP2001504447A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0506651A2 (fr) * | 1991-03-25 | 1992-09-30 | IMMUNO Aktiengesellschaft | Préparations pharmaceutiques sur la base de protéines plasmatiques |
| EP0629347A1 (fr) * | 1992-01-23 | 1994-12-21 | Morinaga Milk Industry Co., Ltd. | Agent antibacterien et traitement d'articles au moyen de cet agent |
| EP0568200A2 (fr) * | 1992-04-02 | 1993-11-03 | Immuno Japan Inc. | Compositions pharmaceutiques et alimentaires contenant des transferrines et des agents antibactériens pour améliorer l'activité des dépenses immunitaires et pour le traitement d'infections |
| EP0730868A1 (fr) * | 1995-02-17 | 1996-09-11 | Tamotsu Satoh | Médicaments formulés pour le traitement d'inflammations orales et produits alimentaires préparés pour le traitment et la prévention de la stomatite |
| EP0753308A2 (fr) * | 1995-07-12 | 1997-01-15 | Gambit International Limited | Utilisation de lactoferrine pour la thérapie de maladies infectieuses aigues ou récurrentes causées par Streptococcus pyogenes ou d'autres bactéries pathogènes gram-positives intracellulaires |
| WO1997005884A1 (fr) * | 1995-08-07 | 1997-02-20 | New England Medical Center Hospitals, Inc. | Aliment lacte pour nourrissons et additifs correspondants |
Non-Patent Citations (5)
| Title |
|---|
| CHEMICAL ABSTRACTS, Volume 124, No. 24, 10 June 1996, (Columbus, Ohio, USA), page 1, Abstract No. 325373; & JP,A,08 059 500, (SHIMAMURA SEIICHI et al.), (05-03-96). * |
| DIALOG INFORMATION SERVICE, File 155, Medline, Dialog Accession No. 07325914, Medline Accession No. 93146928, BELLAMY W. et al., "Antibacterial Spectrum of Lactoferricin B, a Potent Bactericidal Peptide Derived from the N-Terminal Region of Bovine Lactoferrin"; & J. APPL. BACTERIOL. (ENGLAND), Dec. 1992, 73(6), p * |
| FILE WPI, Derwent Accession No. 96-350155, KURIIWA N., "Drug for Inhibition of Endotoxin-Induced Inflammation Comprises Peptide of Mol. Wt. 10000, Derived from N-Terminal Region of Comprises Peptide of Mol. Wt. 1000, Derived from N-Terminal Region of Lactoferrin"; & JP,A,08 165 248, (25-06-96), DW9635. * |
| PATENT ABSTRACTS OF JAPAN, Vol. 88, No. 27; & JP,A,63 051 337 (SNOW BRAND MILK PROD CO LTD), 4 March 1988. * |
| PATENT ABSTRACTS OF JAPAN, Vol. 96, No. 29; & JP,A,07 309 771 (MORINAGA MILK IND CO LTD), 28 November 1995. * |
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0980261A4 (fr) * | 1997-05-03 | 2003-04-23 | Univ Texas | Methodes de prevention et de traitement du desequilibre metabolique induit par insulte chez les humains et des animaux |
| JP2010090162A (ja) * | 1998-07-06 | 2010-04-22 | Pharmasurgics In Sweden Ab | 人ラクトフェリンの配列に基づくペプチドおよびその使用 |
| US7803757B2 (en) | 1998-07-06 | 2010-09-28 | Pharmasurgics In Sweden Ab | Peptides based on the sequence of human lactoferrin and their use |
| US7253143B1 (en) | 1998-07-06 | 2007-08-07 | Pharmasurgics In Sweden Ab | Peptides based on the sequence of human lactoferrin and their use |
| WO2000001730A1 (fr) * | 1998-07-06 | 2000-01-13 | A+ Science Invest Ab | Peptides reposant sur la sequence de la lactoferrine humaine et leur utilisation |
| US9109048B2 (en) | 1998-08-21 | 2015-08-18 | Lytix Biopharma As | Inhibition of tumor growth |
| WO2000012541A3 (fr) * | 1998-08-28 | 2000-06-08 | Alpharma As | Peptides bioactifs |
| US8143211B2 (en) | 1998-08-28 | 2012-03-27 | Lytix Biopharma As | Bioactive peptides |
| US7439228B2 (en) | 1998-08-28 | 2008-10-21 | Lytix Biopharma As | Bioactive peptides |
| US6890902B2 (en) | 1998-08-28 | 2005-05-10 | Alpharma As | Cytotoxic modified lactoferrin peptides |
| US8283315B2 (en) | 1998-08-28 | 2012-10-09 | Lytix Biopharma As | Inhibition of tumour growth |
| WO2000012542A3 (fr) * | 1998-08-28 | 2000-06-29 | Alpharma As | Peptides bioactifs |
| WO2001019852A3 (fr) * | 1999-08-31 | 2002-09-12 | Alpharma As | Preparation de peptides |
| US7393824B1 (en) | 2000-03-09 | 2008-07-01 | Lytix Biopharma | Methods of peptide preparation |
| JP2002241301A (ja) * | 2001-02-15 | 2002-08-28 | Meiji Milk Prod Co Ltd | 炎症に伴う症状の軽減剤 |
| US8703699B2 (en) | 2002-04-03 | 2014-04-22 | Auckland Uniservices Limited | Lactoferrin |
| WO2003082921A1 (fr) * | 2002-04-03 | 2003-10-09 | Fonterra Research Centre Limited | Lactoferrine |
| US7446089B2 (en) | 2002-04-18 | 2008-11-04 | Singh Pradeep K | Methods of inhibiting and treating bacterial biofilms by metal chelators |
| US8343911B2 (en) | 2002-04-18 | 2013-01-01 | University Of Iowa Research Foundation | Methods of inhibiting and treating bacterial biofilms by metal chelators |
| WO2003088914A3 (fr) * | 2002-04-18 | 2004-02-26 | Univ Iowa Res Found | Procede pour inhiber et traiter de films biologiques au moyen de chelateurs metalliques |
| US8242079B2 (en) | 2002-05-10 | 2012-08-14 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| US7901879B2 (en) | 2002-05-10 | 2011-03-08 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| GB2396810A (en) * | 2002-12-20 | 2004-07-07 | Richard John Cleeve | Bird Feed |
| US8105615B2 (en) | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| RU2398575C2 (ru) * | 2004-06-23 | 2010-09-10 | Нестор Медикал Аб | Композиция, содержащая молочную кислоту и лактоферрин |
| WO2006001766A1 (fr) * | 2004-06-23 | 2006-01-05 | Nestor Medical Ab | Composition comprenant de l'acide lactique et de la lactoferrine |
| US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| US7420033B2 (en) | 2004-10-26 | 2008-09-02 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| WO2009050279A1 (fr) | 2007-10-19 | 2009-04-23 | Pharmasurgics In Sweden Ab | Nouveaux peptides synthétiques et leur utilisation |
| US8815812B2 (en) | 2007-11-14 | 2014-08-26 | Inger Mattsby-Baltzer | Synthetic arginine substituted peptides and their use |
| EP2661180B1 (fr) | 2011-01-05 | 2016-09-28 | MJN U.S. Holdings LLC | Composition contenant des protéines de lait thermolabiles et procédé de préparation associé |
| CN103338657A (zh) * | 2011-01-05 | 2013-10-02 | Mjn美国控股有限责任公司 | 包含热不稳定乳蛋白的组合物及其制备方法 |
| WO2012094098A1 (fr) * | 2011-01-05 | 2012-07-12 | Mead Johnson Nutrition Company | Composition contenant des protéines de lait thermolabiles et procédé de préparation associé |
| US9132165B2 (en) | 2011-01-26 | 2015-09-15 | Pergamum Ab | Synthetic peptides and their use |
| EP2481751A1 (fr) | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Homme peptides dérivés de lactoferrine |
| US8846608B2 (en) | 2011-01-26 | 2014-09-30 | Pergamum Ab | Human lactoferrin derived peptides and their use |
| WO2012101157A1 (fr) | 2011-01-26 | 2012-08-02 | Pharmasurgics In Sweden Ab | Peptides dérivés de la lactoferrine humaine et leur utilisation |
| WO2012101156A2 (fr) | 2011-01-26 | 2012-08-02 | Pharmasurgics In Sweden Ab | Nouveaux peptides synthétiques et leur utilisation |
| WO2014097123A1 (fr) | 2012-12-17 | 2014-06-26 | Progine Farmaceutici S.R.L. | Composition pour application topique comprenant de la lactoferrine |
| EP2992894A1 (fr) | 2014-09-05 | 2016-03-09 | Progine Farmaceutici Srl | Formulations vaginales pour prévenir et traiter des infections vaginale et cervico-vaginale |
| WO2021222584A3 (fr) * | 2020-04-29 | 2021-12-02 | The Regents Of The University Of Michigan | Inhibition d'entrée virale du sras-cov-2 par administration de lactoferrine et ses utilisations |
| CN116036054A (zh) * | 2023-03-07 | 2023-05-02 | 广州见华医学科技有限公司 | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 |
| CN116327740A (zh) * | 2023-03-07 | 2023-06-27 | 广州见华医学科技有限公司 | 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途 |
| CN116036054B (zh) * | 2023-03-07 | 2024-04-26 | 湖北嫦娥生物股份有限公司 | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 |
| CN116327740B (zh) * | 2023-03-07 | 2024-07-02 | 苏州青珩信息科技有限公司 | 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途 |
| EP4523699A1 (fr) * | 2023-09-15 | 2025-03-19 | FB Dermo srl | Composition dermatologique anti-inflammatoire comprenant du glycerophosphoinositol, un hydrolysat de lactoferrine et un cannabinoïde, notamment pour le traitement de la dermatite séborrhéique |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3872797A (en) | 1998-03-06 |
| CA2263416A1 (fr) | 1998-02-19 |
| EP0920331A1 (fr) | 1999-06-09 |
| JP2001504447A (ja) | 2001-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0920331A1 (fr) | Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine | |
| Togawa et al. | Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance | |
| Egea et al. | GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa | |
| Inoue et al. | Composition and physiological functions of the porcine colostrum | |
| Broide et al. | Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice | |
| Iigo et al. | Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine | |
| Conti et al. | Cultures of astrocytes and microglia express interleukin 18 | |
| Ginkel et al. | Partial IgA-deficiency with increased Th2-type cytokines in TGF-β1 knockout mice | |
| Ogawa et al. | Regulated production of the chemokine CCL28 in human colon epithelium | |
| Fu et al. | The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. | |
| KR100297959B1 (ko) | 유장단백질로hiv-혈청양성개체의치료방법 | |
| IL129211A (en) | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders | |
| Bodammer et al. | Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin | |
| Crocker et al. | Regulation of a murine macrophage haemagglutinin (sheep erythrocyte receptor) by a species-restricted serum factor | |
| JP4668534B2 (ja) | 免疫反応を調節するためのエナメルマトリックスタンパク質組成物 | |
| Yanagi et al. | In VivoRole of IL-10 and IL-12 during Development of Sjögren's Syndrome in MRL/lprMice | |
| JPH06503320A (ja) | 再活性化酸素種に対する防御剤の使用 | |
| Faust et al. | In vitro Modulation of C1q mRNA Expression and Secretion by Interleukin-1, Interleukin-6, and Interferon-g in Resident and Stimulated Murine Peritoneal Macrophages | |
| EP0950416B1 (fr) | Utilisation de TCF-II pour le traitement de la perte de poids corporel, l'anémie et l'élévation de TNF causées par le cancer | |
| US6613741B2 (en) | Method for treating aseptic SIRS in humans and other animals | |
| Ohtsuka et al. | Changes in mRNA of immune factors expressed by milk somatic cells of Holstein cows with hypocalcemia after calving | |
| JP4787445B2 (ja) | 抗原特異的ＩｇＥ抗体産生抑制剤 | |
| AU732053B2 (en) | Agents for the prevention and/or treatment of radiation-induced disorders | |
| Faist et al. | Posttraumatic immune suppression as initiator of organ failure | |
| Rana et al. | Iron binding and receptor: lactoferrin and tonb receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE ES FI FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1997935939 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 509640 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1998 509640 Kind code of ref document: A Format of ref document f/p: F |
|
| ENP | Entry into the national phase |
Ref document number: 2263416 Country of ref document: CA Ref country code: CA Ref document number: 2263416 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09248287 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997935939 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997935939 Country of ref document: EP |